๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
CONMED Corporation (CNMD)
NYSE: CNMD ยท Real-Time Price ยท USD
46.56
+0.18 (0.39%)
Nov 20, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

Markets were described as stable, while AirSeal and Buffalo Filter offer growth opportunities through laparoscopic adoption and smoke-evacuation legislation. BioBrace distributor changes are expected to conclude in H1 2027; 2027 margins face cost headwinds.

Young Li
MedTech Analyst, Jefferies

All right, why don't we get this session started? Thanks, everyone, for coming. My name is Young Li, one of the Jefferies MedTech analysts, and really pleased to be hosting management from CONMED. We have Pat Beyer, President and CEO, and John Gallagher, EVP and CFO of the company. Gentlemen, welcome to our conference.

Pat Beyer
President and CEO, CONMED

Thank you. Glad to be here.

John Gallagher
EVP and CFO, CONMED

Yeah, thank you.

Young Li
MedTech Analyst, Jefferies

All right, great. I guess, why don't we start off a little bit high level, because it's kind of topical. Some of the MedTech peer companies have kind of called out some market softness, especially for the more elective type of procedures within orthopedics. What's CONMED seeing from your perspective in terms of your end markets, both for the ortho business as well as for general surgery?

Pat Beyer
President and CEO, CONMED

Young, good question. Again, we're in different segments than what we typically are hearing companies talk about, total joints, hips, and knees, be that. We're seeing stability there, and we're seeing the same thing on the general surgery side. I would also say the size of our market share also tells us that we should be able to weather those headwinds that hit us better than a larger MedTech company with larger market share. Our outlook is stability, and we're not saying anything differently right now.

Young Li
MedTech Analyst, Jefferies

Okay, great. Is it fair to assume that's what you're expecting for next year as well?

Pat Beyer
President and CEO, CONMED

We are, yeah.

Young Li
MedTech Analyst, Jefferies

Good. I guess, wanted to focus on AirSeal. It's a topic that gets a lot of attention from investors. I guess, you are trying to expand into the laparoscopic segment more and more. How's that transition going, both in the U.S. and, I think, OUS, you do better and more laparoscopic procedures. How's the trend in the OUS side as well?

Pat Beyer
President and CEO, CONMED

Young, when we think about AirSeal, we think about it as a platform that helps us drive our global general surgery business. In quarter three, we grew 6.4%, so we really like where we're at globally. On the AirSeal side, we have two specific markets we target, soft tissue robotics and the world of laparoscopy. Both are growth opportunities, not just in the U.S., but also internationally. We have a history of driving penetration in the laparoscopic market internationally. We have pivoted in the U.S. in the last couple of years to include that in our portfolio of offense, not just the robotic side, but also the laparoscopic side, and we're seeing uptakes on that. What you're seeing from that is, you're seeing our capital sales in the U.S. accelerate from quarter one and quarter two, and continue to be strong for us.

Young Li
MedTech Analyst, Jefferies

Okay. It's a big, relatively untapped opportunity. It's about 3 million procedures in the U.S. Where do you think that penetration can go? Can you sort of compare it relative to where you are on the robotic side?

Pat Beyer
President and CEO, CONMED

Yeah. So, we say we're 6%-7% penetrated in the U.S. on a TAM of about 3 million procedures. We see that continuing to grow. We believe we'll be in the double digit/higher double digit market share in the coming years. On the robotic side, the opportunity for us has been to partner with the soft tissue robotic companies where their portfolio takes care of every patient. We have been typically used in the robotic side on the more acute patients. So, our penetration on the robotic side has typically been in the 30%-40% range. There's no reason to say over time we wouldn't be in that type of market share, Young.

Young Li
MedTech Analyst, Jefferies

Okay, great. What about the selling process? How different is it? I think, historically, your reps would just basically follow the Intuitive installs and then try to get a placement there. How is it different in the lap channel?

Pat Beyer
President and CEO, CONMED

In the lap channel, it shouldn't be any more different. The opportunity for us in the last years was robotics was growing fast, and we had enough to say grace over in that world. Now we're pivoting and going into laparoscopy, and in laparoscopy, we drive single-digit stable pressure laparoscopy. Better patient outcomes, better economic outcomes. The higher the acuity of the patient, the better the outcomes and the better the economic portfolio. New data that we're seeing is showing fast procedures, like a lap chole that are only 30 minutes, are also seeing clinical and economic value from an AirSeal portfolio. The other challenge I would say to our sales force has been to promote standardization. We do not want a surgeon to use CONMED insufflation on one cohort of patients and then move the AirSeal out of the room and bring in another insufflator.

There's no reason that clinician has to do that. We want to standardize our insufflation portfolio across every procedure the hospital does.

Young Li
MedTech Analyst, Jefferies

Okay, great. What about the OUS laparoscopic opportunity? Can you maybe talk about that market a little bit more? How big is it? How penetrated is it, the growth rate? And why is OUS laparoscopic relatively successful compared to the U.S.?

Pat Beyer
President and CEO, CONMED

Yeah. Young, as we look at OUS laparoscopic, it's harder to get specific data where we're penetrated because we go through a lot of distributors. So that clarity of market share by geography is more difficult to get ahold of. When I think about OUS laparoscopy, there was an opportunity that presented because the robotic opportunity was not there. Less soft tissue robots were internationally. So we had an amazing clinical platform that our sales professionals were driving into laparoscopy. Now what's happening is the robotic opportunity is there, which is providing another engine to that vehicle we have. In the laparoscopic opportunity internationally, I think we're still fairly lowly penetrated. It might be 6%-7% in the United States. It's probably mid-teens to high teens internationally. There's a lot of runway still internationally in the laparoscopic area.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. All right, great. I think AirSeal, it's a great product, especially for complex and high acuity type of procedures. I guess within the robotic category, what percentage of those procedures would you consider complex and high acuity, and what's AirSeal's attachment to those type of procedures?

Pat Beyer
President and CEO, CONMED

What we've said and what we've seen historically is, for example, on the Xi robots, we're getting between 35% and 40% of those procedures. Those are the higher acuity patients where the surgeons are preferring and, quite honestly, demanding AirSeal. With the dV5, which has a built-in insufflator, we are seeing between 15% and 20% of the procedures being done on us. So those acuity patients are being segmented from just acuity to high acuity. So we're getting about 15%-20% of those today. Again, remember, dV5's in the early days of, early years of its launch. We're learning more every day, and the patients that we are seeing done on AirSeal are growing consistently quarter on quarter with the dV5 robot.

Young Li
MedTech Analyst, Jefferies

Okay, great. I guess, now that you are somewhat competing but also partnering together, how's that relationship with Intuitive Surgical been? How's that changed?

Pat Beyer
President and CEO, CONMED

Young, it's a fair question. I think where we don't compete is patient outcomes. When we come into a hospital and say our focus is patient outcomes and economic outcomes, and it's got to be win-win, good things happen. We saw that with the recent FDA approval we had for the indication for AirSeal with the dV5 and the hex cannula. What that did is it gave our sales professionals, and quite honestly, the Intuitive sales professionals, confidence and clarity. Both organizations put out press releases to their teams stating, "We can now comfortably and convincingly tell our surgeons and our customers AirSeal can be used confidently with the dV5." We continue to focus on patients and outcomes. Good things happen there.

Young Li
MedTech Analyst, Jefferies

Okay, great. You do have a pretty robust clinical dossier for AirSeal. It's been out there a while. Some of the KOLs that we speak to, they don't fully recognize the clinical value of that. We're talking about things like lower procedure times, faster recovery, lower pain, things like that. What c an you do to get that word out there a little bit more in the community, clinician community?

Pat Beyer
President and CEO, CONMED

Yeah. Again, Young, you're right to recognize we have a pretty strong compendium of clinical data, scientific publication, scientific data. But the data doesn't have as much value if the clinicians aren't seeing it. We're challenging our organization to do a better job on the podium, do a better job on publication, using social media. You would have seen at the most recent Society of Robotic Surgery that happened in India, five different robotic companies had live procedures, and every robot used AirSeal and shared the clinical data why they chose that. I think it's an ownership we have to take ownership on. We can't wait for the surgeons to come to us and do their own digging. While we want them to be curious, and they are, we've got to do a better job telling our story.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. All right. You're more and more focused in the ASC setting. How big is that channel currently, and how big can it grow in the next three to five years?

Pat Beyer
President and CEO, CONMED

It's a growing channel. We're seeing a number of the more complex procedures being done in the hospital. Hospitals are moving lower acuity procedures to the ASC. We're seeing that grow. We're seeing it grow with multiple robotic companies. We are in ASCs today with multiple robotic companies. We see that growing and becoming more important. But the important thing to realize is, you're going to move a procedure that we're already getting today in the hospital to the ASC. For us, it's important for us to be in both locations. It's not one plus one is two, it's one is one. We've got to make sure we're in both places to capture those procedures.

Young Li
MedTech Analyst, Jefferies

And then just in terms of the pipeline for AirSeal specifically, are there any updates coming that we should be aware of? What should be the right cadence for product updates in that category?

Pat Beyer
President and CEO, CONMED

Yeah, Young, in the last couple years, we've focused on the trocar and the integration with the robotic companies. You're right to expect, innovation plays a large role in MedTech. You'll see AirSeal technology around the actual insufflation unit become to evolve, and you should see that in the coming years, more new technology around single-digit low-pressure laparoscopy and how our technology can help the surgeons better navigate what is single-digit laparoscopy and the data around that.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. Why don't we move on to other segments of the business? So Buffalo Filter, so that's the smoke evac product. The category, I think you estimated, it's around $1 billion. Can you maybe just talk about how fast the market is growing, the U.S./OUS split, and how big can that market grow to?

Pat Beyer
President and CEO, CONMED

Well, we don't think the market's $1 billion now. We think it's in the mid $300 million-$400 million. We think it'll grow to $1 billion. We think it's highly legislative-driven, and we know the U.S. has a number of states that have passed legislation. Canada has also passed legislation, as has some of the Australian provinces, states, and the Nordic region. We see it growing fast. We think today it's growing in the low double digits, and that's what we're seeing there.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. Okay. The branded business is doing really well. You have leadership there. The OEM side, you don't focus as much on. I think it decreased in 3Q. I guess the question is, at what point would the OEM business sort of become small enough where it wouldn't be very material to our numbers?

Pat Beyer
President and CEO, CONMED

Yeah. Young, just to remind the world, when we bought Buffalo Filter, we acquired a business that was the manufacturer of our smoke pencil. They were supplying for us. When we bought Buffalo Filter, there were a number of OEM customers that we had. We have taken that from 20+ to a handful today. Today, our challenge is we generate strong cash from it, but it's incredibly unpredictable. We'll continue to navigate how do we get more predictability, less volatility, and work that down over time until it's either predictable and stable with one or two large OEM customers of ours, or it disappears completely. We've made progress over the last years. You'll see continued progress in 2027.

Young Li
MedTech Analyst, Jefferies

All right, great. There's going to be a competitive product launch in mid-next year. How does Buffalo Filter stack up versus the competition? How often do you see Stryker, and what's your win rate against them?

Pat Beyer
President and CEO, CONMED

Yeah. This is a competitive market, smoke evacuation. We believe it's more than a two-horse race, but in general, it's us and Stryker who compete for the business. We do well against Stryker, and where we do well against Stryker is where better matters. Our filter is 99.9997% efficacy. We launched a new pump last year called PX5. We know smoke evacuation is more than just removing the smoke. It's removing the smoke safely. It's toxic, it's carcinogenic. Where clinicians and hospitals want better protection for their theater staff, their operating room staff, we win. Our compelling value proposition is better outcomes, better surgeon, better caregiver care. Stryker does a good job. They've got a very competitive product. We focus on the clinical efficacy of our portfolio.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. You mentioned legislation. I think there are 23 states that have legislation for smoke evac, covering around 60% of the U.S. population.

I think there are 10 more on deck. What are some of the major ones, I think, remaining? Massachusetts, Texas, Florida. When do you think they will get legislation?

Pat Beyer
President and CEO, CONMED

Young, I am going to go to you and get some facts on when they are going to go, because we do not know. We think there are about 10 more states on the slate. We do know that Pennsylvania just passed. John, we have been looking hard at the flow of when these states come in and when they do not. Pennsylvania is a bit of an outlier there in the way they have approached it, isn't it?

John Gallagher
EVP and CFO, CONMED

Yeah, exactly, Pat. I think that the legislation tailwind will be a sustaining factor in achieving the growth for Buffalo Filter. Pennsylvania was a recent one where a departure from what we saw with other states is that they put a 90-day window to get compliant with smoke-free operating rooms. In other instances, we have seen a longer tail, it might be 12-18 months. They are the first state to do that. As we look forward, not only is this tailwind behind the Buffalo Filter business going to continue to accelerate the growth that we see, but we think that the legislation in the future, there is opportunity for the window to be shorter, which presents a great opportunity for our sales force in these states. Pennsylvania is the first case in point for that.

Young Li
MedTech Analyst, Jefferies

All right. When I find out, I'll let you know.

Pat Beyer
President and CEO, CONMED

Just let us know first.

Young Li
MedTech Analyst, Jefferies

Absolutely. Turning to your third growth driver, within orthopedics, the BioBrace product. I guess maybe just on the quarter, so Q3, it grew well, OUS. I think U.S. was a little bit challenged. You highlighted some of the commercial organization strengthening initiatives that you've done that's impacting that business. Can you maybe just give us an update where you are with that, and when do you think that business can turn around in the U.S.?

Pat Beyer
President and CEO, CONMED

Yeah. Global orthopedics grew 7.2%. We were teens internationally. We were down 1.7% in the United States. BioBrace grew globally really strong. Quarter three, quarter four, 2025, and quarter one, 2026, we grew mid-single digits in the United States. We've got some strong tailwinds of we're on offense. The supply chain challenges we had were history. We're now on offense. We've got strong supply. We've got a great growth driver in BioBrace, and the United States was starting to accelerate, but we saw a number of territories that when the cloud of supply chain is removed, we saw a weakness in some distributors, and we proactively made the decision, now is the time to strengthen them, when the global business is in a strong position. We made that change in quarter one and quarter two. We saw the business slow down in quarter two.

We saw the business slow down in quarter three. We've made a number of the distributor changes already. We expect to be through that in the first half of 2027, and we expect to be growing as we exit 2027 first half. What we're seeing already is, and what we've consistently seen is, the areas in the U.S. that we did not make the changes have continued to grow.

Young Li
MedTech Analyst, Jefferies

Okay, great. BioBrace has a pretty wide indication. I think it's been used in more than 70 different type of soft tissue procedures, but you do focus on a few big ones, rotator cuffs and ACLs. How are the targeted indications growing and doing for you in the U.S.?

Pat Beyer
President and CEO, CONMED

Yeah, if we think about BioBrace, again, it's the only FDA-approved augmentation approved for anywhere soft tissue weakness exists. So, it's got strength and healing. Our three primary areas are rotator cuff, ACL, and Achilles. So, you've got these three large clinical indications. We not only have strong penetration in the U.S. continuing to drive there, we also have the clinical data being built in the U.S. so that when we get international indications, and in the international world, you have to get a specific procedure indication. It's not broad like the U.S. So, we will be driving for indications in the shoulder, in the knee, and in the Achilles internationally, and they're going well.

Young Li
MedTech Analyst, Jefferies

Okay, great. What's driving the strength internationally for you? You have some approvals in countries in Europe and Asia, I guess, Brazil recently. Other major countries that we should expect approval for next? What about Western Europe, the big countries there?

Pat Beyer
President and CEO, CONMED

Yeah, Young, we also have another one of our strong markets is Korea, South Korea. We have a great business there. We got approval last October, and we are seeing great uptake in it. We expect Western Europe to get their approvals in 2028. We have a strong international orthopedic sports med business. When we bring in a best-in-class clinical solution like BioBrace to a strong sales professional team, great things happen.

Young Li
MedTech Analyst, Jefferies

All right. Then, maybe turning to the numbers. You guys have been growing mid-single digits top line pretty consistently. Maybe consensus has around 10% EPS growth during that time. Is that the right algorithm to think about CONMED going forward?

John Gallagher
EVP and CFO, CONMED

Yeah, I mean, we are not guiding 2027 here today, but I would say, Young, that the mid-single digit growth is where our actuals have been. We have a number of initiatives in place to accelerate that, but for the moment, I would say mid-single digits is sort of the right area. On earnings growth, the 10% on EPS growth is where we position the business. But keep in mind, as we look at next year, we do have some gross margin headwinds as we look at raw material prices, freight and transport prices, all are increasing, which would be a headwind to our typical growth profile there.

Young Li
MedTech Analyst, Jefferies

Mm-hmm. Then, maybe lastly, just on M&A. Your leverage ratio is pretty healthy, dropped to 2.7x . What is the interest level on M&A right now? What is your pipeline looking? How are the valuations out there in the market looking?

John Gallagher
EVP and CFO, CONMED

Yeah, we're pleased with the deleveraging profile. We'll continue to delever. We could probably take out some more debt, but as you pointed out, we're at a position right now where we do have some M&A capacity. It's going to be valuation contingent. We're looking, so we're certainly evaluating both in general surgery as a key point of interest, but in ortho also. As I mentioned, valuation dependent and balancing that with share repurchases, we look at our own company's valuation and thinking about that. More to come on capital allocation as we get into the Q4 call.

Young Li
MedTech Analyst, Jefferies

All right, great. I think that's all the time we have. Really appreciate the updates. Thank you.